| 9.37 0.05 (0.54%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.14 | 1-year : | 13.01 |
| Resists | First : | 9.54 | Second : | 11.14 |
| Pivot price | 8.42  |
|||
| Supports | First : | 8.06 |
Second : | 7.15 |
| MAs | MA(5) : | 8.9 |
MA(20) : | 8.32 |
| MA(100) : | 9.13  |
MA(250) : | 12.65 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 74.5 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 23.18 | Low : | 5.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RLAY ] has closed below upper band by 0.7%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.54 - 9.57 | 9.57 - 9.6 |
| Low: | 9.01 - 9.05 | 9.05 - 9.09 |
| Close: | 9.3 - 9.36 | 9.36 - 9.42 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 07 Dec 2023
Will Relay Therapeutics Inc (RLAY) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Wed, 06 Dec 2023
Relay Therapeutics Inc (RLAY) has gained 17.49% in a Week, Should You Buy? - InvestorsObserver
Mon, 04 Dec 2023
Relay Therapeutics Inc (RLAY) Stock: What Does the Chart Say Monday? - InvestorsObserver
Thu, 30 Nov 2023
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a Bet - Yahoo Finance
Tue, 14 Nov 2023
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth - Simply Wall St
Thu, 02 Nov 2023
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 8.56e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 13,770 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.6349e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -296.8 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 153.87 |
| Sales Per Share | 1.7551e+007 |
| EBITDA (p.s.) | 938776 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -268 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.17 |
| Dividend | 0 |
| Forward Dividend | 1.464e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|